Edition:
India

Natus Medical Inc (BABY.OQ)

BABY.OQ on NASDAQ Stock Exchange Global Select Market

36.75USD
22 Jun 2018
Change (% chg)

$0.45 (+1.24%)
Prev Close
$36.30
Open
$36.35
Day's High
$37.50
Day's Low
$36.05
Volume
216,199
Avg. Vol
87,449
52-wk High
$43.55
52-wk Low
$28.05

Select another date:

Fri, Jun 22 2018

Hedge fund Voce's nominees elected to Natus board

June 22 Natus Medical Inc said on Friday its stockholders had elected hedge fund Voce Capital Management's nominees to the company's board, ending a months long proxy fight.

UPDATE 1-In Natus proxy fight, Glass Lewis supports Voce nominees

BOSTON, June 13 Influential proxy-advisory firm Glass Lewis & Co recommended that Natus Medical Incorporated shareholders remove two company nominated directors and replace them with hedge fund Voce Capital Management's nominees.

In Natus proxy fight, Glass Lewis supports Voce nominees

BOSTON, June 13 Influential proxy-advisory firm Glass Lewis & Co recommended that Natus Medical Incorporated shareholders remove two company nominated directors and replace them with hedge fund Voce Capital Management's nominees.

BRIEF-Voce Catalyst Urges Natus Medical Shareholders To Vote For Election Of Its Nominees, Removal Of Co's Chairman

* VOCE CATALYST PARTNERS LP URGES NATUS MEDICAL INC SHAREHOLDERS TO VOTE FOR ELECTION OF ITS NOMINEES AND FOR REMOVAL OF CO'S CHAIRMAN

BRIEF-Natus Medical Reports Q1 Non-GAAP Earnings Per Share Of $0.24

* Q1 EARNINGS PER SHARE VIEW $0.24 -- THOMSON REUTERS I/B/E/S

BRIEF-Natus Medical Inc Confirms Receipt Of Notice From Voce Capital

* NATUS CONFIRMS RECEIPT OF NOTICE OF VOCE CAPITAL’S INTENT TO NOMINATE DIRECTOR CANDIDATES TO REPLACE 50% OF THE NATUS BOARD

BRIEF-Natus Announces $30 Million Share Repurchase Program

* NATUS MEDICAL - TO USE CASH ON HAND, CASH GENERATED FROM OPERATIONS, EXISTING CREDIT FACILITIES OR OTHER FINANCING TO FUND SHARE REPURCHASE PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Natus Medical Announces 2018 Annual And First Quarter Financial Guidance

* REVENUE IN Q4 WAS LOWER THAN EXPECTED DUE TO WEAKNESS IN OUR U.S. NEURODIAGNOSTIC BUSINESS

Select another date: